NOVELLUS
Factor Bioscience LLC
Mark For: NOVELLUS® trademark registration is intended to cover the categories of
| Research |
OneLook
Acronym Finder
|
| Serial Number | 88028436 |
| Registration Number | 6008685 |
| Mark Literal Elements | NOVELLUS |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | TRADEMARK |
| Register | PRINCIPAL |
| Current Location | PUBLICATION AND ISSUE SECTION 2020-02-06 |
| Basis | 1(a) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | Yes |
| Current Use | Yes |
| Intent To Use | No |
| Filed ITU | No |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Rachelle A. Dubow, Esq. |
| Attorney Docket Number | 107541-0038 |
| Law Office Assigned | L40 |
| Employee Name | BRADLEY, EVELYN W |
Timeline
| 2018-07-06 | Application Filed |
| 2018-10-27 | Status: Live/Pending |
| 2019-01-02 | Location: TMEG LAW OFFICE 104 - EXAMINING ATTORNEY ASSIGNED |
| 2019-01-02 | Transaction Date |
| 2019-06-18 | Published |
| 2019-06-18 | Published for Opposition |
| 2019-10-01 | Date of First Use |
| 2019-10-01 | Date of Use In Commerce |
| 2020-02-06 | Location: PUBLICATION AND ISSUE SECTION |
| 2020-03-10 | Status: Registered. The registration date is used to determine when post-registration maintenance documents are due. |
| 2020-03-10 | Trademark Registered |
Trademark Parties (Applicants & Owners)
| Party: |  Factor Bioscience LLC |
| Address | Suite 17B 1035 Cambridge Street Cambridge, MASSACHUSETTS UNITED STATES 02141 |
| Legal Entity Type | Limited Liability Company |
| Legal Entity State | DELAWARE |
Documents
 Drawing | JPEG | 2018-07-06 |
| Specimen | JPEG | 2018-07-06 |
 TEAS RF New Application | MULTI | 2018-07-06 |
| XSearch Search Summary | XML | 2018-10-26 |
| XSearch Search Summary | XML | 2018-10-26 |
| Offc Action Outgoing | XML | 2018-10-27 |
| Response to Office Action | MULTI | 2019-02-12 |
| Amendment and Mail Process Complete | MULTI | 2019-02-20 |
| Offc Action Outgoing | XML | 2019-04-10 |
| Examiners Amendment | XML | 2019-05-09 |
| Amendment and Mail Process Complete | MULTI | 2019-05-10 |
| Examiners Amendment | XML | 2019-05-10 |
| Amendment and Mail Process Complete | MULTI | 2019-05-11 |
| TRAM Snapshot of App at Pub for Oppostn | MULTI | 2019-05-11 |
| Notice of Publication | XML | 2019-05-29 |
| Notification Of Notice of Publication | XML | 2019-05-29 |
| OG Publication Confirmation | XML | 2019-06-18 |
| Notice of Allowance | APPLICATION/XML | 2019-08-13 |
| Specimen | JPEG | 2019-12-18 |
| Statement of Use | MULTI | 2019-12-18 |
| ITU Unit Action | APPLICATION/XML,IMAGE/JPEG | 2019-12-31 |
| Notice of Acceptance of Statement of Use | XML | 2020-02-07 |
| TRAM Snapshot of App at Pub for Oppostn | MULTI | 2020-02-07 |
| Registration Certificate | 2020-03-10 |
Attorney of Record
Good, Services, and Codes
IC 001. US 001 005 006 010 026 046. G & S: Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering. FIRST USE: 20191001. FIRST USE IN COMMERCE: 20191001
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factors, namely, pharmaceutical preparations for use in cell therapy for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing, for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease. FIRST USE: 20140400. FIRST USE IN COMMERCE: 20140400
IC 009. US 021 023 026 036 038. G & S: Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments. FIRST USE: 20191108. FIRST USE IN COMMERCE: 20191108
IC 042. US 100 101. G & S: Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing. FIRST USE: 20140400. FIRST USE IN COMMERCE: 20140400
| International Codes: | 1 |
| U.S. Codes: | 001,005,006,010,026,046 |
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 9 |
| U.S. Codes: | 021,023,026,036,038 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0421 | Pharmaceutical research and development services; Pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; Pharmaceutical research and development services, namely, gene-editing services, mRNA engineering services, cell reprogramming services, and cell therapy development services; scientific laboratory services, namely, stem cell production services; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services, namely, gene-editing services |
| GS0011 | Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| REGISTERED-PRINCIPAL REGISTER | 2020-03-10 | |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2020-02-07 | |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2020-02-06 | |
| STATEMENT OF USE PROCESSING COMPLETE | 2019-12-29 | 66230 |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2019-12-29 | 66230 |
| USE AMENDMENT FILED | 2019-12-18 | 66230 |
| TEAS STATEMENT OF USE RECEIVED | 2019-12-18 | |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2019-08-13 | |
| PUBLISHED FOR OPPOSITION | 2019-06-18 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-06-18 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-05-29 | |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2019-05-10 | 6328 |
| EXAMINERS AMENDMENT E-MAILED | 2019-05-10 | 6328 |
| EXAMINERS AMENDMENT -WRITTEN | 2019-05-10 | 78439 |
| EXAMINER'S AMENDMENT ENTERED | 2019-05-10 | 88888 |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2019-05-10 | |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2019-05-09 | 6328 |
| EXAMINERS AMENDMENT E-MAILED | 2019-05-09 | 6328 |
| EXAMINERS AMENDMENT -WRITTEN | 2019-05-09 | 78439 |
| EXAMINER'S AMENDMENT ENTERED | 2019-05-09 | 88888 |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2019-04-10 | |
| FINAL REFUSAL WRITTEN | 2019-04-10 | 78439 |
| FINAL REFUSAL E-MAILED | 2019-04-10 | |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-02-19 | 66121 |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-02-19 | 66121 |
| ASSIGNED TO LIE | 2019-02-18 | 66121 |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-02-12 | |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2018-10-27 | 6325 |
| NON-FINAL ACTION WRITTEN | 2018-10-27 | 78439 |
| NON-FINAL ACTION E-MAILED | 2018-10-27 | 6325 |
| ASSIGNED TO EXAMINER | 2018-10-25 | 78439 |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-07-12 | |
| NEW APPLICATION ENTERED IN TRAM | 2018-07-10 |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 